Patents Issued in September 20, 2018
  • METHODS USING 3-(4-AMINO-1-OXO-1,3-DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE FOR TREATMENT OF MANTLE CELL LYMPHOMAS
    Publication number: 20180263968
    Abstract: Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 20, 2018
    Inventor: Jerome B. Zeldis
  • COMPOSITIONS AND METHODS FOR TREATING BACTERIAL INFECTIONS
    Publication number: 20180263969
    Abstract: Pharmaceutical compositions and methods for treating bacterial infections are disclosed.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Applicant: WOCKHARDT LIMITED
    Inventors: Mahesh Vithalbhai PATEL, Sachin BHAGWAT, Prasad Keshav DESHPANDE
  • COMPOUNDS AND METHODS USEFUL FOR TREATING OR PREVENTING HEMATOLOGICAL CANCERS
    Publication number: 20180263970
    Abstract: The present invention includes methods of treating patients with acute myeloid leukemia across a range of genetic subtypes with DHODH inhibitors, such as 6-fluoro-2-(2?-fluoro-[1,1?-biphenyl]-4-yl)-3-methylquinoline-4-carboxylic acid).
    Type: Application
    Filed: August 29, 2016
    Publication date: September 20, 2018
    Applicants: THE BROAD INSTITUTE, INC., THE GENERAL HOSPITAL CORPORATION, PRESIDENT AND FELLOWS OF HARVARD COLLEGE, BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: David B. Sykes, David Scadden, Timothy A. Lewis, Andreas Janzer, Hanna Meyer, Detlef Stöckigt
  • COMBINATION OF TOPOISOMERASE-I INHIBITORS WITH IMMUNOTHERAPY IN THE TREATMENT OF CANCER
    Publication number: 20180263971
    Abstract: The present disclosure relates to compositions and methods for treating cancer, more specifically to methods and compositions comprising a Topoisomerase I inhibitor and an ?-PD-L1 antibody
    Type: Application
    Filed: September 16, 2016
    Publication date: September 20, 2018
    Inventors: Patrick HWU, Jodi A. MCKENZIE, Rina M. MBOFUNG, Rodabe AMARIA
  • ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE
    Publication number: 20180263972
    Abstract: The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 20, 2018
    Inventors: Chengzhi Zhang, Jim Kerr
  • COCRYSTALS OF NALOXONE AND NALTREXONE
    Publication number: 20180263973
    Abstract: This invention relates to cocrystals of naloxone and of naltrexone and their use as opioid antagonists. The cocrystals of the invention include naloxone isonicotinamide cocrystal, naloxone hydrochloride piperazine cocrystal, naltrexone menthol cocrystal, naltrexone thymine cocrystal, naltrexone 2,5-dihydroxybenzoic acid cocrystal, naltrexone salicylic acid cocrystal, naltrexone hydrochloride piperazine cocrystal and naltrexone hydrochloride sulfathiazole cocrystal. A drug-in¬ adhesive transdermal patch containing the opioid analgesic fentanyl or an analog thereof and a cocrystal of naloxone or naltrexone is disclosed. Also disclosed is a method of treating pain, such as acute, chronic or intermittent pain, by applying a drug-in-adhesive transdermal patch of the invention to the skin of a patient in need thereof.
    Type: Application
    Filed: September 26, 2016
    Publication date: September 20, 2018
    Applicant: Pain Therapeutics, Inc.
    Inventors: Remi BARBIER, Nadav FRIEDMANN, Vijay SRIRAMBHATLA, Stephen WATT, Michael ZAMLOOT
  • CRYSTALLINE SALTS OF NALOXONE AND NALTREXONE
    Publication number: 20180263974
    Abstract: This invention relates to crystalline salts of naloxone and of naltrexone and their use as opioid antagonists. The crystalline salts of the invention include naloxone saccharinate, naltrexone succinate and a methanol solvate of naltrexone succinate. A drug-in-adhesive transdermal patch containing the opioid analgesic fentanyl or an analog thereof and a crystalline salts of naloxone or naltrexone is disclosed. Also disclosed is a method of treating pain, such as acute, chronic or intermittent pain, by applying a drug-in-adhesive transdermal patch of the invention to the skin of a patient in need thereof.
    Type: Application
    Filed: September 26, 2016
    Publication date: September 20, 2018
    Applicant: Pain Therapeutics, Inc.
    Inventors: Remi BARBIER, Nadav FRIEDMANN, Vijay SRIRAMBHATLA, Stephen WATT, Michael ZAMLOOT
  • Methods Of Treating Motor And Movement Disorders And Side Effects Thereof Associated with Parkinson's Disease Treatments
    Publication number: 20180263975
    Abstract: This invention provides methods of treating motor disorder side effects associated with the administration of levodopa to a subject having Parkinson's disease, by administering eltoprazine or a pharmaceutically acceptable acid addition salt thereof in doses and dosing schedules which result in beneficial antidyskinetic effects for the subject. In particular, the invention provides methods for reducing dyskinesia associated with Parkinson's disease treatments, and effective doses and dosing regimens of eltoprazine or a pharmaceutically acceptable acid addition salt thereof.
    Type: Application
    Filed: January 13, 2016
    Publication date: September 20, 2018
    Inventors: David A. Lowe, Charlotte Keywood
  • COMPOSITION AND METHOD FOR TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS
    Publication number: 20180263976
    Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Applicant: Glytech LLC
    Inventor: Daniel C. Javitt
  • CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR
    Publication number: 20180263977
    Abstract: Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
    Type: Application
    Filed: April 4, 2018
    Publication date: September 20, 2018
    Applicant: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Hong Jia, Guangxiu Dai
  • Bromocriptine Formulations
    Publication number: 20180263978
    Abstract: The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 20, 2018
    Inventors: Anthony H. Cincotta, Craig Michael Bowe, Paul Clark Stearns, Laura Jean Weston
  • COMBINATION OF RAF INHIBITORS AND AURORA KINASE INHIBITORS
    Publication number: 20180263979
    Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering Raf inhibitors in combination with Aurora kinase inhibitors. The present disclosure relates to methods of treating subject suffering from cancer, comprising administering to the subject a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and an Aurora kinase inhibitor or a pharmaceutically acceptable salt thereof; the amount of said Raf kinase inhibitor or a pharmaceutically acceptable salt thereof being such that the combination thereof is therapeutically effective in the treatment of the cancer. In some [embodiments, the cancer is a solid tumor cancer.
    Type: Application
    Filed: December 22, 2015
    Publication date: September 20, 2018
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Viviana BOZON, Katherine M. GALVIN
  • STABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A PYRIMIDINE-SULFAMIDE
    Publication number: 20180263980
    Abstract: The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof
    Type: Application
    Filed: February 20, 2018
    Publication date: September 20, 2018
    Applicant: ACTELION PHARMACEUTICALS LTD.
    Inventors: Charles Tokunbo Adesuyi, Bruce Hamilton Lithgow, Olivier Lambert, Lovelace Holman
  • SUBSTITUTED 5-FLUORO-1H-PYRAZOLOPYRIDINES AND THEIR USE
    Publication number: 20180263981
    Abstract: The present application relates to novel substituted 5-fluoro-1H-pyrazolopyridines, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases, and to their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 20, 2018
    Applicant: ADVERIO PHARMA GMBH
    Inventors: Markus FOLLMANN, Johannes-Peter STASCH, Gorden REDLICH, Jens ACKERSTAFF, Nils GRIEBENOW, Walter KROH, Andreas KNORR, Eva-Maria BECKER, Frank WUNDER, Volkhart Min-Jian LI, Elke HARTMANN, Joachim MITTENDORF, Karl-Heinz SCHLEMMER, Rolf JAUTELAT, Donald BIERER
  • CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATION
    Publication number: 20180263982
    Abstract: The invention provides methods and compositions that are useful for treating allergic diseases, bacterial infections, fungal infections, viral infections, mastocytosis, mast cell-mediated inflammation and parasite infections (e.g., helminth infections).
    Type: Application
    Filed: August 12, 2016
    Publication date: September 20, 2018
    Applicant: Rutgers, The State University of New Jersey
    Inventor: Mark C. Siracusa
  • COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE
    Publication number: 20180263983
    Abstract: In one aspect, the invention relates to compositions comprising at least one creatine or creatine analog, at least one omega-3 fatty acid, and citicoline analogs. Also disclosed are methods of using same, alone or in combination with other agents, to treat depression disorders and associated maladies. Also disclosed are methods of using same, alone or in combination with other agents, to improve neuropsychological performance. Also disclosed are methods of using same, alone or in combination with other agents, to improve complexion. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: March 8, 2018
    Publication date: September 20, 2018
    Inventors: Perry Renshaw, Deborah Yurgelun-Todd
  • SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS
    Publication number: 20180263984
    Abstract: Compounds of Formula I: and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
    Type: Application
    Filed: October 4, 2017
    Publication date: September 20, 2018
    Inventors: Shelley Allen, Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Lily Huang, Yutong Jiang, Timothy Kercher, Jeongbeob Seo
  • MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV
    Publication number: 20180263985
    Abstract: Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR8 and pharmaceutically acceptable salts thereof, useful in treating HIV infections.
    Type: Application
    Filed: September 13, 2016
    Publication date: September 20, 2018
    Inventors: ROMAS GELEZIUNAS, JOSEPH E. HESSELGESSER, JASMINE KAUR, JEFFREY PATRICK MURRY, DEREK DEAN SLOAN
  • TREATMENT OF ALOPECIA AREATA
    Publication number: 20180263986
    Abstract: The present invention provides a novel treatment of alopecia areate. The problem to be solved by the invention is to provide a new pharmaceutical use of 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile. A therapeutic or preventive agent for alopecia areata, containing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile as an active ingredient.
    Type: Application
    Filed: September 22, 2016
    Publication date: September 20, 2018
    Applicants: LEO Pharma A/S, Japan Tobacco Inc.
    Inventors: Michael SIERRA, Tord LABUDA, Atsuo TANIMOTO, Yuichi SHINOZAKI
  • TREATING MELANOMA WITH MEBENDAZOLE AND A MITOGEN-ACTIVATED KINASE INHIBITOR
    Publication number: 20180263987
    Abstract: Provided herein are methods for treating melanoma in a subject.
    Type: Application
    Filed: March 16, 2018
    Publication date: September 20, 2018
    Applicant: GEORGETOWN UNIVERSITY
    Inventors: Sivanesan Dakshanamurthy, Stephen W. Byers, Dean Rosenthal
  • SUBSTITUTED PYRAZOLOPYRIMIDINES AS GLUCOCEREBROSIDASE ACTIVATORS
    Publication number: 20180263988
    Abstract: Substituted pyrazolopyrimidines and dihydropyrazolopyrimidines and related compounds, their methods of manufacture, compositions containing these compounds, and methods of use of these compounds in treating lysosomal storage disorders such as Gaucher disease are described herein. The compounds are of general Formula (I) in which variables R1-R7 and X are described in the application.
    Type: Application
    Filed: May 18, 2018
    Publication date: September 20, 2018
    Inventors: Juan Jose Marugan, Noel Southall, Ehud Goldin, Wei Zheng, Samarjit Patnaik, Ellen Sidransky, Omid Motabar, Wendy Westbroek
  • THERAPEUTIC APPROACHES FOR TREATING PARKINSON'S DISEASE
    Publication number: 20180263989
    Abstract: The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.
    Type: Application
    Filed: May 21, 2018
    Publication date: September 20, 2018
    Applicant: Pharnext
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov
  • CARDIO- AND RENOPROTECTIVE ANTIDIABETIC THERAPY
    Publication number: 20180263990
    Abstract: The present invention relates to a certain DPP-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.
    Type: Application
    Filed: May 22, 2018
    Publication date: September 20, 2018
    Inventors: Odd-Erik JOHANSEN, Maximilian VON EYNATTEN, Thomas KLEIN, Hans-Juergen WOERLE
  • COMPLEXES AND SALTS OF DIHYDROPYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN PHARMACEUTICALS
    Publication number: 20180263991
    Abstract: This invention relates to L-tartaric acid complexes, acid addition salts, base addition salts of the compound named (S)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl) methyl) morpholine-3-carboxylic acid or tautomer thereof and pharmaceutical compositions thereof, and further relates to use of the compounds or the pharmaceutical compositions in the manufacture of a medicament, especially for use in preventing, managing, treating or lessening a HBV infection. The complex, acid addition salt or base addition salt of the present invention is crystalline form, substantially crystalline form, polymorphism, amorphism, hydrate or solvate.
    Type: Application
    Filed: February 1, 2016
    Publication date: September 20, 2018
    Applicant: SUNSHINE LAKE PHARMA CO., LTD
    Inventors: Qingyun Ren, Liang CHEN, Xinchang LIU, Jinsheng LIANG, Chenliang WU, Zhifu ZOU, Guanghua YAN, Desheng HUANGFU, Siegfried GOLDMANN, Yingjun ZHANG
  • TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20180263992
    Abstract: Methods for the prevention and treatment of neurodegenerative diseases, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS), is described, as well as compositions and combined preparations for use in the methods. The methods comprise inhibiting EGFR signalling, and inhibiting MyD88-dependent TLR/IL-R1 signalling, in the central nervous system of a subject in need of such prevention or treatment. The compositions comprise an inhibitor of EGFR signalling, and an inhibitor of MyD88-dependent TLR/IL-R1 signalling.
    Type: Application
    Filed: September 23, 2016
    Publication date: September 20, 2018
    Inventors: Peter RICHARDSON, Richard MEAD, Laura FERRAIUOLO, Kenneth Patrick MULVANY
  • METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-IV
    Publication number: 20180263993
    Abstract: The present invention related to a method of preventing and/or treating chronic traumatic encephalopathy.
    Type: Application
    Filed: October 25, 2017
    Publication date: September 20, 2018
    Inventor: Robert Vink
  • Benzimidazole Derivatives as PI3 Kinase Inhibitors
    Publication number: 20180263994
    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazoles compounds for treating cancer.
    Type: Application
    Filed: January 9, 2018
    Publication date: September 20, 2018
    Inventors: Rosanna TEDESCO, Junya QU, Robert SANCHEZ, Ralph A. RIVERO
  • GENERATION OF MUSCLE LINEAGE CELLS AND THERAPEUTIC USES THEREOF
    Publication number: 20180263995
    Abstract: Methods and compositions for producing mature myotubes are provided herein. In some instances, the method involves contacting a myoblast in an in vitro culture with a compound, wherein the contacting the myoblast in the in vitro culture with the compound results in generation of mature myotubes or myotube-like cells. In some cases, methods of treatment are provided involving treating a subject with a compound such as a Chk1 inhibitor in order to treat muscle deficiency. The compound may be administered as a stand-alone therapy or in combination with a cell therapy, such as introduction of muscle precursor cells such as satellite cells or myoblasts. Methods for identifying compounds that induce formation of mature myotubes or myotube-like cells from myoblasts are also provided herein, as well as methods of using the identified compounds to treat subjects.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Inventors: Uli SCHMIDT, Anabel DE LA GARZA, Alexander KISELYOV
  • ARYL SULTAM DERIVATIVES AS RORc MODULATORS
    Publication number: 20180263996
    Abstract: Compounds of the formula I: or a pharmaceutical salt thereof, wherein p, s, A, R3 and Re are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: December 19, 2017
    Publication date: September 20, 2018
    Applicant: Genentech, Inc.
    Inventors: Olivier RENE, Benjamin FAUBER, David VESEY, Paul WINSHIP, Tammy LADDUWAHETTY
  • PHARMACEUTICAL COMPOSITIONS COMPRISING A JAK INHIBITOR
    Publication number: 20180263997
    Abstract: Pharmaceutical compositions comprising filgotinib maleate Form I and uses thereof are described herein.
    Type: Application
    Filed: March 12, 2018
    Publication date: September 20, 2018
    Inventors: David Alonzo, Bei Li, Dimitrios Stefanidis
  • PHARMACEUTICAL COMPOSITION OF FUSED AMINODIHYDROTHIAZINE DERIVATIVE
    Publication number: 20180263998
    Abstract: The present invention provides a pharmaceutical composition comprising a compound represented by formula (1): or N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide, or a pharmaceutically acceptable salt of the foregoing, and a salt of a compound having a C12-22 saturated aliphatic hydrocarbon group.
    Type: Application
    Filed: October 8, 2015
    Publication date: September 20, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Zaima, Kazuo Kazama, Shuntaro Arase, Kentaro Nagane, Kanta Horie, Yosuke Ueki
  • METHODS OF SYNTHESIS AND/OR PURIFICATION OF DIAMINOPHENOTHIAZINIUM COMPOUNDS
    Publication number: 20180263999
    Abstract: Disclosed are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (“diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (Methylene Blue), and the resulting high purity characterized by a purity greater than 98%, and very low levels of heavy metals and organic impurities Azure A, B, C and MVB. Also disclosed are methods of treatment of a tauopathy or methemoglobinemia in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the high-purity diaminophenothiazinium compound.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Applicant: WISTA LABORATORIES LTD.
    Inventors: Claude Michel WISCHIK, John Mervyn David STOREY, Colin MARSHALL, James Peter SINCLAIR, Thomas Craven BADDELEY
  • COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF
    Publication number: 20180264000
    Abstract: The present invention provides modulators of protein function, to restore protein homeostasis, including GSPT1 activity. The invention provides methods of modulating protein-mediated diseases, such as GSPT1-mediated diseases, disorders, conditions, or responses. Compositions are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as GSPT1-mediated diseases, disorders, and conditions, including cancer and astrogliosis.
    Type: Application
    Filed: March 9, 2018
    Publication date: September 20, 2018
    Inventors: Kyle W.H. Chan, Paul E. Erdman, Leah Fung, Frank Mercurio, Robert Sullivan
  • SUSTAINED RELEASE OLANZAPINE FORMULATIONS
    Publication number: 20180264001
    Abstract: The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Inventors: Mark Alan Smith, Carine Claassen-Punt
  • RNA POLYMERASE I INHIBITORS AND USES THEREOF
    Publication number: 20180264002
    Abstract: Provided are novel compounds which are capable of inhibiting an activity of RNA polymerase I, and uses thereof in treating diseases or disorders modulated by RNA polymerase I, preferably autoimmune diseases such as multiple sclerosis and proliferative diseases.
    Type: Application
    Filed: June 4, 2018
    Publication date: September 20, 2018
    Applicant: Tel HaShomer Medical Research Infrastructure and Services Ltd.
    Inventors: Anat Achiron, Roi Mashiach, Michael Gurevich
  • INHIBITORS OF THE PLASMODIAL SURFACE ANION CHANNEL AS ANTIMALARIALS
    Publication number: 20180264003
    Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.
    Type: Application
    Filed: May 21, 2018
    Publication date: September 20, 2018
    Applicant: The United States of America, as represented by the Secretary, Department of Health and Human
    Inventors: Sanjay A. Desai, Ajay D. Pillai
  • NOVEL CHEMOIMMUNOTHERAPY FOR EPITHELIAL CANCER
    Publication number: 20180264004
    Abstract: The invention provides a method for treating cancer in a subject in need thereof, wherein said subject comprises cancer tissue that ‘contains epithelial cancer cells and immunosuppressive 8 cells, and wherein said method comprises administering to said subject a therapeutically effective amount of a) one or more first composition that pauses—immunogenic eel’ death and/or of said epithelial cancer cells, and b) one or more second composition that reduces one or both of the number and function of said immunosuppressive B cells in said cancer.
    Type: Application
    Filed: March 17, 2016
    Publication date: September 20, 2018
    Applicant: The Regents of the University of California
    Inventors: Michael Karin, Shabnam Shalapour
  • METHODS OF TREATING ERECTILE DYSFUNCTION
    Publication number: 20180264005
    Abstract: An active agent for use in a method of, or for use in the preparation of a medicament for, treating or inhibiting the development of erectile dysfunction and/or incontinence following pelvic radiation treatment in a subject in need thereof, comprising administering said subject an active agent in a treatment effective amount, is described. The active agent has the general structure of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Inventors: James D. Crapo, Rebecca Oberley Deegan
  • COMPOSITIONS COMPRISING TRITERPENOIDS
    Publication number: 20180264006
    Abstract: The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating for use in treating a condition selected from Alzheimer's disease (AD), Parkinson's Diseases (PD) and vascular dementia (VD).
    Type: Application
    Filed: September 22, 2016
    Publication date: September 20, 2018
    Applicant: REGENERA PHARMA LTD.
    Inventors: Zadik HAZAN, Konstantin ADAMSKY, Andre C. B. LUCASSEN, Nurit NOVAK
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20180264007
    Abstract: A pharmaceutical composition is described. The composition comprises at least one mometasone compound selected from mometasone, pharmaceutically acceptable salts of mometasone, prodrugs of mometasone, solvates of mometasone, solvates of pharmaceutically acceptable salts of mometasone and solvates of prodrugs of mometasone and a propellant component comprising 1,1-difluoroethane (R-152a). In a preferred embodiment, the composition further comprises at least one formoterol compound selected from formoterol, pharmaceutically acceptable salts of formoterol, prodrugs of formoterol, solvates of formoterol, solvates of pharmaceutically acceptable salts of formoterol and solvates of prodrugs of formoterol.
    Type: Application
    Filed: December 2, 2016
    Publication date: September 20, 2018
    Inventors: Stuart Corr, Timothy James NOAKES
  • COMBINATION
    Publication number: 20180264008
    Abstract: A novel combination comprising a 17 ?-hydroxylase/C17,20 lyase inhibitor, for example: (3?)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol or a pharmaceutically acceptable salt or ester thereof, and an AKT inhibitor, for example: N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of 17 ?-hydroxylase/C17,20 lyase and/or AKT inhibition is beneficial, e.g., cancer.
    Type: Application
    Filed: May 21, 2018
    Publication date: September 20, 2018
    Inventors: Mark J. Cornfeld, Rakesh Kumar, Shannon Renae Morris
  • METHOD OF PREVENTING OBESITY AND CARDIOVASCULAR PROBLEMS IN POULTRY
    Publication number: 20180264009
    Abstract: Provided is a feed for ameliorating weight gain in poultry comprising 25-hydroxy vitamin D, canthaxanthin, Vitamin E and Vitamin C. Animals fed this composition gained weight, but did not become obese, nor did they experience adverse effects associated with hyperphagia related obesity. This feed also provides numerous cardiovascular benefits.
    Type: Application
    Filed: January 15, 2016
    Publication date: September 20, 2018
    Inventors: Shuen Ei CHEN, Thau Kiong CHUNG
  • COMBINATION OF 25-HYDROXYVITAMIN D AND ANTIOXIDANTS/ANTI-INFLAMMATORIES FOR BOVINE HEALTH
    Publication number: 20180264010
    Abstract: This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid, vitamin E and at least one carotenoid) to make a pharmaceutical, nutraceutical or food supplement which can ameliorate various problems observed in bovines connected cystic ovarian disease, or increasing 17-? estradiol levels. Feed and premixes containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.
    Type: Application
    Filed: January 15, 2016
    Publication date: September 20, 2018
    Inventors: Pietro CELI, Shuen Ei CHEN, Thau Kiong CHUNG
  • COMPANION ANIMAL FEED WITH COMBINATION OF 25-HYDROXYVITAMIN D AND ANTIOXIDANTS/ANTI-INFLAMMATORIES
    Publication number: 20180264011
    Abstract: This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants/anti-inflammatories (ascorbic acid vitamin E and canthaxanthin) to make a premix or feed which can ameliorate various problems observed in companion animals which have been subject to overfeeding. Foods containing the 25-OH D3 and antioxidants/anti-inflammatories and premixes are also provided.
    Type: Application
    Filed: January 15, 2016
    Publication date: September 20, 2018
    Inventors: Shuen Ei CHEN, Thau Kiong CHUNG
  • COMBINATION OF 25-HYDROXYVITAMIN D AND ANTI-INFLAMMITORIES FOR SUSTAINED PLASMA 17- ß ESTRADIOL LEVELS
    Publication number: 20180264012
    Abstract: This invention relates to the use of the combination of 25-hydroxyvitamin D3 (“25-OH D3”) and antioxidants (ascorbic acid vitamin E and canthaxanthin) to make a premix or feed for use in maintain, increasing, or ameliorating the decrease of 17 ?-estradiol levels in poultry which are observed when poultry is fed ad libitum, thereby extending the poultry's egg laying life.
    Type: Application
    Filed: January 15, 2016
    Publication date: September 20, 2018
    Inventors: Shuen Ei CHEN, Thau Kiong CHUNG
  • COMPOSITION AND METHODS FOR TREATING SLEEP DISORDERS
    Publication number: 20180264013
    Abstract: A method for treating sleep disorders includes the step of administering to a subject in need therefor a pharmaceutical composition comprising one or more analgesic agents. Also disclosed is a pharmaceutical composition for treating sleep disorders. The pharmaceutical composition comprises one or more analgesic agents and an anti-insomnia agent.
    Type: Application
    Filed: May 21, 2018
    Publication date: September 20, 2018
    Inventor: David A. DILL
  • COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
    Publication number: 20180264014
    Abstract: Provided are compositions and methods for treating multiple sclerosis (MS). One embodiment of the disclosed method entails orally administering to a MS patient a first amount of aspirin and a second amount of fumaric acid or an ester or a salt thereof. In some embodiments, the aspirin is administered at from about 80 mg to about 500 mg per day and the fumaric acid or ester or salt thereof is administered at about 360 mg per day.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 20, 2018
    Inventor: Joseph Habboushe
  • LEUKOCYTE INFILTRATION PROMOTING AGENT AND ANTITUMOR IMMUNOSTIMULATORY AGENT
    Publication number: 20180264015
    Abstract: A lysophospholipid receptor-activating substance is able to normalize abnormal blood vessels in tumors without affecting normal blood vessels and to thus induce or promote infiltration of leukocytes into the whole or partial region of a tumor. Therefore, such a lysophospholipid receptor-activating substance is useful as a leukocyte infiltration promoter and an antitumor immunostimulant. Moreover, such a lysophospholipid receptor-activating substance can enhance cancer immunotherapy when used in combination with cancer immunotherapy, and is therefore useful as an agent for enhancing cancer immunotherapy.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 20, 2018
    Applicant: OSAKA UNIVERSITY
    Inventors: Nobuyuki TAKAKURA, Hisamichi NAITO, Kazuhiro TAKARA
  • DOSAGE FORMS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE
    Publication number: 20180264016
    Abstract: Osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions.
    Type: Application
    Filed: May 17, 2018
    Publication date: September 20, 2018
    Inventor: Herriot Tabuteau
  • CARBORANE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180264017
    Abstract: Disclosed herein are compounds comprising dicarba-closo-dodecaborane. The compounds can be, for example, estrogen receptor beta (ER?) agonists. In some examples, the compounds can be selective ER? agonists. Also provided herein are methods of treating, preventing, or ameliorating cancer in a subject, suppressing tumor growth in a subject, treating an inflammatory disease in a subject, treating a neurodegenerative disease in a subject, treating a psychotropic disorder in a subject, or a combination thereof by administering to a subject a therapeutically effective amount of one or more of the compounds or compositions described herein, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 19, 2016
    Publication date: September 20, 2018
    Applicants: OHIO STATE INNOVATION FOUNDATION, INSTITUTE OF MOLECULAR GENETICS AS CR, V.V.I.
    Inventors: Werner TJARKS, Petr BARTUNEK, David SEDLAK